Kaitu Pharmaceuticals: Wholly-owned Subsidiary Signs Strategic Cooperation Agreement with Funuo Pharmaceuticals Involving Development of KT-939 Raw Material Whitening and Spot-removal Cosmetics

LightningPacketLoss

2026-03-13 02:40:40

Abstract generation in progress

Recently, Kaitu Pharmaceutical announced that its wholly-owned subsidiary, Suzhou Kaitu Pharmaceutical Co., Ltd., signed a strategic cooperation agreement with Zhejiang Funuo Medical Co., Ltd. on March 12, 2026.

The agreement involves joint development of a whitening and anti-spot cosmetic product containing the company’s innovative raw material KT-939, aimed at assisting in alleviating and improving skin pigmentation.

Under the cooperation, Suzhou Kaitu will supply KT-939 raw material to Funuo Medical and authorize them to develop, produce, and sell whitening and anti-spot products with KT-939 as the core active ingredient in mainland China.

Both parties will conduct in-depth collaboration on technological improvements and end-product development to accelerate the research, registration, and production of specialized cosmetics with KT-939, with Funuo Medical responsible for sales.

The company plans to use the cash flow generated from the KT-939 cosmetic raw material business to support the development and commercialization of core products KX-826, GT20029, and other pipeline products.

(Kaitu Pharmaceutical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.